Navigation Links
Geisinger study: Inflammatory disease causes blindness
Date:6/16/2008

DANVILLE, PA. People suffering from a type of connective tissue disease characterized by inflammation of arteries in the head are three times more likely to experience blindness, new Geisinger research shows.

In a study published in a recent edition of the Journal of Clinical Pathology, Geisinger researchers examined a disorder known as temporal arteritis. In this disease, arteries swell and restrict blood flow to the brain.

Temporal arteritis can cause headaches, jaw soreness and flu-like symptoms. Untreated, the disease can lead to blindness or stroke. The average age for disease onset is 70.

Giant cells, which are white blood cells that destroy bacteria, are often found in patients with the disease. The Geisinger study found that patients with giant cells are far more prone to blindness compared to patients without these cells.

The study also found that patients with giant cells are three times more likely to experience Polymyalgia rheumatica, an inflammatory disorder that causes muscle aches and stiffness primarily in the arms, thighs and neck.

"We need to learn more about how these giant cells work so we can limit the effects of this disease, which can cause significant problems if ignored," said Geisinger rheumatologist and lead study author Thomas Harrington, MD.


'/>"/>

Contact: Justin Walden
jawalden@Geisinger.edu
570-271-8083
Geisinger Health System
Source:Eurekalert

Page: 1

Related biology news :

1. Study: diabetic neuropathy costs billions per year in lost work time
2. Study: Fountain of youth for your heart?
3. First-ever study: lack of critical lubricant causes wear in joints
4. Mayo Clinic study: Ossurs collars superior in immobilization and reduction of pressure
5. Study: weight-loss tips differ in African-American, mainstream magazines
6. Smithsonian study: Sediment prediction tools off the mark
7. Mouse study: When it comes to living longer, its better to go hungry than go running
8. Scientists successfully treat new mouse model of inflammatory bowel disease
9. Rong Li Lab identifies new role of inflammatory protein in PKD and a possible treatment
10. Antioxidant overload may underlie a heritable human disease
11. Gender, coupled with diabetes, affects vascular disease development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... RPS ... clinical study that demonstrates the accuracy of the FebriDx® test, a commercially-ready, ... acute bacterial and viral respiratory tract infections by testing the body’s immune ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
Breaking Biology Technology: